

Neurotech

9 March 2021

Neurotech Secures Strategic Cultivation Partnership with CannaPacific

Highlights:

- **NTI secures strategic Cultivation partnership with CannaPacific to grow and maintain NTI / Dolce medicinal cannabis genetic stock.**
- **Further clinical trials are planned for calendar Q2 / Q3 to further assess the safety and efficacy of NTI / Dolce strains in a broader patient population in respect of autism and related neurological disorders. This Cultivation Partnership supports NTI's preparation for extended patient numbers for expanded phase I/II trials.**
- **CannaPacific partnership to also assist in the development of varietal elite strains developed by Dolce Cann through their exclusive licencing agreement with NTI.**
- **CannaPacific operates a full cGMP Medicinal Cannabis Supply Chain which is underpinned by a licenced cultivation facility in northern NSW.**

Neurotech International Limited (ASX: NTI) ("Neurotech" "NTI" or "the Company") is pleased to announce a strategic cultivation partnership with CannaPacific Limited ("CannaPacific") to grow and maintain genetic stock and assist in the development of elite varietal strains developed by NTI and Dolce Cann through their exclusive licencing agreement. Following successful outcome of the Phase I/II clinical trials starting this quarter, the partnership enables NTI to prepare for expanded clinical studies in larger patient groups moving into calendar Q2 and Q3 as the current trial parameters are intended to form the basis for larger future studies which will assess the efficacy of these strains in a broader patient population in respect of autism and related neurological disorders.

CannaPacific will house the genetic stock and assist in the development of NTI's exclusively licensed Dolce varietal strains within CannaPacific's Northern NSW cultivation facility. CannaPacific is licenced and permitted by the Australian Government (Office of Drug Control) to cultivate and research medicinal cannabis which is a requirement to commence sales under the TGA Special Access Scheme.

CannaPacific CEO, Joshua Dennis said *"CannaPacific is delighted to work with the NTI/Dolce team to assist in providing a GMP supply chain for their unique varieties within our Northern NSW facility. We're creating an agricultural innovation hub for companies who wish to enter the medicinal cannabis space and leverage our existing cultivation and production facility."*

Brian Leedman, Chairman of Neurotech International commented, *"We have previously stated that positive results from our initial trial will pave the way for larger studies to address the unmet need for effective treatments for autism and broader neurological conditions. The partnership with CannaPacific allows NTI to ensure that we can maintain momentum with our clinical studies through quality product supply and importantly, maintain and develop our intellectual property base through our exclusive licensing of the Dolce Cann strains"*.

The agreement between Neurotech and CannaPacific is for an initial period to 30 June 2021 and does not contain provision for termination prior to this date and is subject to mutual due diligence and the receipt of all relevant regulatory approvals. As part of the fees payable, CannaPacific is to be issued 1,000,000 fully paid ordinary shares in the Company upon receipt of an Office of Drug Control permit to produce NTI / Dolce cannabis strains for clinical trials, and a further 1,000,000 fully paid ordinary shares in the Company within five business days of the delivery of the first harvest of dried flower to the Company, or by 1 August 2021 whichever occurs first.

Neurotech International Ltd

ABN 73 610 205 402

Suite 5 CPC, 145 Stirling Highway

Nedlands, Western Australia 6009

www.neurotechinternational.com

Authority

This announcement has been authorised for release by the Board of the Company.

Further Information

Brian Leedman
Chairman
bleedman@neurotechinternational.com
+61 (0)41 228 1780

Winton Willesee
Non-Executive Director
winton@azc.com.au
+61 (0)41 066 7844

About Neurotech

Neurotech International Limited is a medical device and solutions company conducting clinical studies to assess the neuro-protective, anti-inflammatory and neuro-modulatory activities of our proprietary NTI/Dolce cannabis strains. Neurotech is also commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity. For more information about Neurotech and Mente Autism please visit <http://www.neurotechinternational.com>

About CannaPacific:

CannaPacific is an Australian biotechnology company focused on the cannabinoid pharmaceutical sector. By combining advanced molecular breeding technology with a traditional approach to drug development, CannaPacific seeks to build a global therapeutic offering with an initial focus on palliative care and post-traumatic stress disorder. CannaPacific's strategy is to attain a world-leading position in the field of cannabinoid science through the research, development and commercialisation of cannabinoid molecules as authorised pharmaceutical products.

CannaPacific operates a full cGMP Medicinal Cannabis Supply Chain which is underpinned by a licenced cultivation facility nestled in the beautiful Byron Bay hinterland in northern NSW. The production facility includes a 10,000 sqm Dutch glasshouse and high-security outdoor cultivation area.

Neurotech International Ltd

ABN 73 610 205 402
Suite 5 CPC, 145 Stirling Highway
Nedlands, Western Australia 6009
www.neurotechinternational.com